Evaluation of Dose Distribution in Lung Tumor Radiotherapy with Boron Neutron Capture Therapy

Document Type : Original Paper


1 Department of Medical Physics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Department of Radiotherapy and Radiation Oncology, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Department of Medical Physics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

3 Ahvaz Jundishapur University of Medical Sciences

4 Department of Clinical Oncology, Faculty of Medicine, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.


Introduction: It is well known that neutrons are more effective treatments than photons to treat hypoxic tumors due to the interaction with the nucleus and the production of heavy particles. This study aimed to evaluate the suitability of Boron neutron capture therapy (BNCT) for the treatment of lung cancer. To this end, neutron dose distributions were calculated in lung tumor volume and peripheral organs at risk (OARs).
Material and Methods: Dose distribution to treat lung cancer was calculated by MCNPX code.  An elliptical tumor with a volume of 27cm3 was centered in the left lung of the ORNL phantom and was irradiated with neutron spectrums of Massachusetts Institute of Technology (MIT) and CNEA-MEC. The tumor was loaded with different concentrations of Boron 0, 10, 30, and 60 ppm to evaluate the delivered dose to OARs. Results: Neutron absorbed dose rates in the tumor were 2.2×10-3, 2.6×10-3, 3.4×10-3, and 4.7×10-3 Gy/s for boron concentrations of 0, 10, 30, and 60 ppm, respectively for MIT. Moreover, similar results for CNEA-MEC were 1.2×10-3, 1.6×10-3, 2.5×10-3, and 3.7×10-3 Gy/s. The heart absorbed the maximum neutron dose rate of 1.7×10-4 and 1.6×10-4 Gy/s in MIT and CNEA, respectively. For all energy bins of spectrums, the neutrons flux is decreased as it penetrates the lung.
Conclusion: An increase in boron concentrations in tumors increases the absorbed doses while deteriorates dose uniformity. The results show that the MIT source is well suited to treat deep lung tumors while maintaining the OARs’ dose within the threshold dose.


Main Subjects

  1. American Cancer Society. Key Statistics for Lung Cancer. 2019. availible from: https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html.
  2. Bortolussi S, Altieri S. Thermal neutron irradiation field design for boron neutron capture therapy of human explanted liver. Med phys. 2007; 34(12):4700-5.
  3. Khan FM, Gibbons JP. Khan's the physics of radiation therapy: Lippincott Williams & Wilkins; 2014.
  4. Grimes DR, Partridge M. A mechanistic investigation of the oxygen fixation hypothesis and oxygen enhancement ratio. Biomed Phys Eng Express. 2015; 1(4):045209.
  5. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist: Lippincott Williams & Wilkins; 2006.
  6. Mirzaei D, Miri-Hakimabad H, Rafat-Motavalli L. Depth dose evaluation for prostate cancer treatment using boron neutron capture therapy. J Radio Nucl Chem. 2014; 302(3):1095-101.
  7. Yu H, Tang X, Shu D, Liu Y, Geng C, Gong C, et al. Influence of Neutron Sources and 10B Concentration on Boron Neutron Capture Therapy for Shallow and Deeper Non-small Cell Lung Cancer. Health Phys. 2017; 112(3):258-65.
  8. Capoulat M, Kreiner A. A 13 C (d, n)-based epithermal neutron source for Boron Neutron Capture Therapy. Physica Medica. 2017; 33:106-13.
  9. Farías RO, Bortolussi S, Menéndez PR, González SJ. Exploring Boron Neutron Capture Therapy for non-small cell lung cancer. Physica Medica. 2014; 30(8):888-97.
  10. Zolfaghari M, Sedaghatizadeh M. Design and simulation of photoneutron source by MCNPX Monte Carlo code for boron neutron capture therapy. IJMP. 2015; 12(2):129-36.
  11. Riley K, Binns P, Harling O, Albritton J, Kiger W, Rezaei A, et al. An international dosimetry exchange for BNCT part II: Computational dosimetry normalizations. Med phys. 2008; 35(12):5419-25.
  12. Azahra M, Kamili A, Boukhal H. Monte Carlo calculation for the development of a BNCT neutron source (1ev–10keV) using MCNP code. Cancer/Radiotherapie. 2008; 12(5):360-4.
  13. Krstic D, Markovic V, Jovanovic Z, Milenkovic B, Nikezic D, Atanackovic J. Monte Carlo calculations of lung dose in ORNL phantom for boron neutron capture therapy. RPD. 2014; 161(1-4):269-73.
  14. Rahmani F, Shahriari M. Beam shaping assembly optimization of Linac based BNCT and in-phantom depth dose distribution analysis of brain tumors for verification of a beam model. Annal Nucl Ener. 2011; 38(2):404-9.
  15. Moss RL. Critical review, with an optimistic outlook, on Boron Neutron Capture Therapy (BNCT). Applied Radiation and Isotopes. 2014; 88:2-11.
  16. Sweet W, Soloway A, Brownell G. Boron-slow neutron capture therapy of gliomas. Acta Radiologica: Therapy, Physics, Biology. 1963; 1(2):114-21.
  17. Suzuki M, Suzuki O, Sakurai Y, Tanaka H, Kondo N, Kinashi Y, et al. Reirradiation for locally recurrent lung cancer in the chest wall with boron neutron capture therapy (BNCT). International Cancer Conference Journal; 2012: 1(4): 235-238.
  18. Barth RF, Vicente MG, Harling OK, Kiger WS, Riley KJ, Binns PJ, et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol. 2012; 7:146.
  19. Farr LE, Sweet WH, Robertson JS, Foster CG, Locksley HB, Sutherland DL, et al. Neutron capture therapy with boron in the treatment of glioblastoma multiforme. Am J Roentgenol Radium Ther Nucl Med. 1954; 71(2):279-93.
  20. Hatanaka H, Nakagawa Y. Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy. IJROBP. 1994; 28(5):1061-6.
  21. Chanana AD, Capala J, Chadha M, Coderre JA, Diaz AZ, Elowitz EH, et al. Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies. Neurosurgery. 1999; 44(6):1182-93.
  22. Busse PM, Harling OK, Palmer MR, Kiger W, Kaplan J, Kaplan I, et al. A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. Journal of Neuro-oncology. 2003; 62(1):111-21.
  23. Matsumoto T. Monte Carlo simulation of depth–dose distribution in several organic models for boron neutron capture therapy. Nucl InstrumMethods Phys. Res A. 2007; 580(1):552-7.
  24. Koivunoro H, Bleuel D, Nastasi U, Lou T, Reijonen J, Leung K. BNCT dose distribution in liver with epithermal D–D and D–T fusion-based neutron beams. Applied Radiation and Isotopes. 2004; 61(5):853-9.
  25. Yanagie H, Sakurai Y, Ogura K, Kobayashi T, Furuya Y, Sugiyama H, et al. Evaluation of neutron dosimetry on pancreatic cancer phantom model for application of intraoperative boron neutron-capture therapy. Biomedicine & Pharmacotherapy. 2007; 61(8):505-14.
  26. Gupta N, Gahbauer RA, Blue TE, Albertson B. Common challenges and problems in clinical trials of boron neutron capture therapy of brain tumors. J Neurooncol. 2003; 62(1-2):197-210.
  27. Zonta A, Prati U, Roveda L, Ferrari C, Zonta S, Clerici A, et al. Clinical lessons from the first applications of BNCT on unresectable liver metastases. 2006; 41. J. Phys.: Conf. Ser. 2006; 41: 484.
  28. Moss RL. Critical review, with an optimistic outlook, on Boron Neutron Capture Therapy (BNCT). Appl Radiat Isot. 2014; 88:2-11.
  29. AAPM. Neutron Measurements Around High Energy X-ray Radiotherapy Machines. AAPM American Association of Physicists in Medicine. 1986;19.
  30. Naseri A, Mesbahi A. A review on photoneutrons characteristics in radiation therapy with high-energy photon beams. Rep Pract Oncol Radiother. 2010; 15(5):138-44.
  31. Pelowitz DB. MCNPXTM user’s manual. Los Alamos National Laboratory, Los Alamos. 2005.
  32. Cristy M, Eckerman K. Specific absorbed fractions of energy at various ages from internal photon sources. VI. Newborn. ORNL/TM-8381. 1987.
  33. Suryanto A, Herlambang K, Rachmatullah P. Comparison of tumor density by CT scan based on histologic type in lung cancer patients. Acta Med Indones. 2005; 37(4):195-8.
  34. ICRU. ICRU Report No. 44, Tissue substitutes in radiation dosimetry and measurement; Bethesda: ICRU; 1989.
  35. Kiger III W, Sakamoto S, Harling O. Neutronic design of a fission converter-based epithermal neutron beam for neutron capture therapy. Nuclear science and engineering. 1999;131(1):1-22.
  36. Capoulat M, Minsky D, Kreiner A. Computational assessment of deep-seated tumor treatment capability of the 9Be (d, n) 10B reaction for accelerator-based Boron Neutron Capture Therapy (AB-BNCT). Physica Medica. 2014; 30(2):133-46.
  37. ICRP. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37(2-4):1-332.
  38. Rasouli FS, Masoudi SF. Simulation of the BNCT of brain tumors using MCNP code: beam designing and dose evaluation. IJMP. 2012; 9(3):183-92.
  39. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med phys. 2010; 37(8):4078-101.


Volume 18, Issue 1
January and February 2021
Pages 63-69
  • Receive Date: 13 June 2019
  • Revise Date: 01 September 2019
  • Accept Date: 22 December 2019